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1. Introduction
With the contemporary active lifestyle and widespread professionalism in sport, the need
for high-end injury therapies is growing. Conservative principles in managing various
sports injuries usually do not meet the need of athletes and their coaches. In order to achieve
better and faster recovery after injuries, significant effort has been made in the recent decade
among researchers. Local growth factor application, targeted therapies using recombinant
proteins and tissue engineering represent promising groups of future therapeutic options
with promising results.
Healthy tendons and ligaments get injured either by a single application of force or by a re‐
peated or sustained action that alters their mechanical characteristics. Genetic disorders, ag‐
ing, decreased vascularity, endocrine influences, nutritional status, inactivity,
immobilization, and exercise may cause tendon degeneration, thus rendering the tendon or
ligament more susceptible to injury when force is applied. Hypovascularity is hypothesized
to play the major role in this degeneration, both directly by causing an ischaemic environ‐
ment for the fibroblast and indirectly both by contributing to the production of free radicals
and by allowing for tissue hyperthermia to occur. Conservative management, such as rest,
corticosteroid injection, orthotics, ultrasound, laser treatment, or shockwave treatment pro‐
vide pain relief but, when they fail, surgery is required. Local growth factor application and
tissue-engineering strategies, such as the development of scaffold microenvironments, re‐
sponding cells, and signalling biofactors are currently generating potential areas for addi‐
tional prospective investigation in tendon or ligament regeneration.
Cartilage tissue also comprises of limited intrinsic potential for healing due to the lack of
blood supply and subsequent incomplete repair by local chondrocytes with inferior fibrocar‐
tilage formation. Surgical intervention is often the only option, but the repair of damaged
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cartilage is often less than satisfactory, and rarely restores full function or returns the tissue
to its native normal state. The new concept of cartilage tissue preservation uses tissue engi‐
neering technologies, combining new biomaterials as a scaffold, applying growth factors
and using stem cells and mechanical stimulation.
Skeletal muscle, on the other hand, has a great regenerative capacity; however, this process
if often incomplete because of partial fibrous scar formation. Conservative therapies includ‐
ing cryotherapy, resting, physical therapy and pain relief medications don’t often give satis‐
factory results and can even be controversial. While surgery is reserved for bigger tissue
defects, the need for antifibrotic agents to improve muscle repair after injury is obvious.
These and platelet-derived growth factors represent the future of biological therapies for
this common type of sports injury.
Novel tissue-specific therapies are mainly molecular, based on pathophysiological processes
after injury. Although they seem to significantly accelerate healing and shorten the recovery
time, their true goal is to achieve better and more functional repair.
2. Biological therapy for better muscle regeneration
While spontaneous muscle fibre regeneration usually occurs after muscle injury, this process
can often be slow and incomplete and accompanied by fibrotic infiltration, which compro‐
mises the restoration of contractile function [1]. Scar formation is the result of excessive
wound healing leading to a poor functional outcome after trauma and surgery [2]. Success‐
ful muscle repair after injury is important for restoring mobility and patients’ quality of life.
We therefore have an important medical need for drugs that can promote or hasten muscle
fibre regeneration, reduce fibrosis, and enhance muscle function [1].
Despite the clinical significance of muscle injuries, current treatment principles for injured
skeletal muscle lack a firm scientific basis, and are based on performing RICE (Rest, Ice,
Compression, Elevation) and sometimes prescribing non-steroidal anti-inflammatory drugs
(NSAIDs). However, increasing evidence indicates that the administration of NSAIDs de‐
creases regeneration and increases fibrosis by inhibiting inflammation [3, 4].
Incomplete muscle fibre regeneration and fibrotic infiltration can lead to long-term function‐
al deficits and physical incapacitation [1]. In recent years of muscle regeneration research,
many agents have been described to have a significant antifibrotic effect in patients with
heart or kidney disease and systemic sclerosis. Consequently, researchers are testing these
for muscle healing, as therapeutic targets are the same. Although these agents play a life-
saving role in the previously mentioned diseases, their importance for muscle injuries could
be substantial and for athletes specifically, vital.
Transforming growth factor-Beta (TGF-β) and myostatin have been identified as the main
factors that stimulate fibrotic differentiation. It has been shown in In vitro and In vivo studies
that drugs with anti-fibrotic properties that can prevent or minimize scar formation have the
potential of standalone or adjuvant therapies (Table 1). Although the World Anti-Doping
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Agency (WADA) prohibits any use of myostatin inhibitors in athletes, their potential to act
only therapeutically at the site of injury without any performance enhancement may play an
important role in muscle injury therapy in the future. In the following chapters, various
agents are described that reportedly have beneficial effects on muscle healing after injury.
Class Agent
Recombinant proteins
Follistatin
Decorin
Interferon-γ
Suramin
Relaxin
Autologous growth factors Platelet-rich plasma (PrP)
Other bioactive agents
Mannose-6-phosphate (M6P)
N-acetylcysteine (NAC)
Angiotensin receptor blockers (ARBs)
Table 1. Agents with proven anti-fibrotic effects in In vitro or In vivo studies of skeletal muscle regeneration after injury
2.1. Recombinant proteins in muscle regeneration
Follistatin is an autocrine glycoprotein expressed in nearly all tissues of higher animals, with
multiple effects on skeletal muscles as well as other tissues [5]. It is a functional antagonist
of several members of the TGF-β family of secreted signalling factors, including myostatin -
the most powerful inhibitor of muscle growth characterized to date [6, 7]. Follistatin was
previously known as FSH-suppressing protein (FSP) as it was found to have inhibitory ef‐
fect on pituitary secretion of follicle-stimulating hormone (FSH) [8]. Research into the devel‐
opment of therapies to antagonize myostatin has led to the discovery of several new
functions exhibited by follistatin [9]. Several In vivo studies on follistatin have shown that it
directly inhibits myostatin and also reduces myostatin-induced muscle wasting after sys‐
temic administration [5, 10]. In recent research, Zhu et al. reported on the stimulative effect
of follistatin on MyoD, MyF5, and myogenin expression, which are myogenic transcription
factors that promote muscle differentiation. They also showed its inhibitory effect on myo‐
statin, activin A, and TGF-β, all of which are negative regulators of muscle cell differentia‐
tion [9]. Although various myostatin inhibitors have been described, follistatin can modulate
other regulators of muscle mass in addition to myostatin [11]. For example, follistatin ad‐
ministration to MSTN-1- mice caused muscle mass increases beyond that stimulated by my‐
ostatin depletion [12, 13], suggesting that this may be a more potent approach than targeting
myostatin alone. Intramuscular administration of gene therapy vectors expressing follistatin
has increased muscle mass and strength in both young and aged mdx mice, as well as in
nonhuman primates [14]. In order to investigate the mechanisms of the follistatin-induced
muscle hypertrophy, Gilson et al. used irradiation to destroy the proliferative capacity of
satellite cells. They found that not only inhibition of MSTN, but also of activin (ACT) and
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proliferation of satellite cells are involved in follistatin-induced muscle hypertrophy [12].
Follistatin thus might offer a novel therapeutic strategy for muscular injuries and dystrophy
by suppressing the progression of muscle degeneration and permitting skeletal muscle mass
restoration [15]. However, before translating follistatin-based therapies from the bench to
the bedside, clear mechanisms of how follistatin promotes muscle regeneration require ex‐
tensive investigation.
Decorin is a component of the extracellular matrix in all collagen-containing tissues [16] and
is expressed at high levels in skeletal muscle during early development [17]. It is a small leu‐
cine-rich proteoglycan that can modulate the bioactivity of growth factors and act as a direct
signalling molecule to various cells [18]. It was found to neutralize the effects of myostatin
in both fibroblasts and myoblasts. It has been implicated in cell proliferation and differentia‐
tion due to its ability to bind growth factors and has been found to interact with collagen,
fibronectin and thrombospondin, hence influencing processes such as fibrillogenesis, cell ad‐
hesion, and migration [19]. Fukushima et al. proved that decorin also inactivates the stimu‐
lating effect of TGF-β in myofibroblasts In vitro, which has a beneficial effect in muscle
fibrosis and leads to enhancement of muscle regeneration and strength [20]. Recent reports
showed that the injection of decorin into lacerated muscle improves both muscle structure
and function, enabling nearly complete recovery of muscle strength [20-22]. Besides reduc‐
ing fibrosis, decorin promotes muscle cell differentiation by upregulating follistatin,
PGC-1α, and myogenic genes, including MyoD [23]. Thus, decorin appears to be a new mol‐
ecule in the myostatin-signalling pathway [24-26]. It has been reported that muscle cells pro‐
duce decorin and myostatin proteins at the same time, and that prenatal and postnatal
expression of myostatin is similar [17].
Interferon (IFN)-γ is an inflammatory cytokine that was first identified as an antiviral fac‐
tor [27].  A primary function of IFN-γ is activation of macrophages through the classical
pathway, which promotes pathogen killing [28].  Later,  IFN-γ was recognized as a pleio‐
tropic cytokine that also plays a role in regulating different immune responses as well as
influencing many physiological processes [29]. It has also been shown by Foster et al. in
2003  to  not  only  down-regulate  endogenous  collagen expression,  but  also  to  effectively
block TGFβ -mediated increases in collagen protein levels [30]. INF-y also inhibits TGFβ
signalling by inducing expression of SMAD 7, which participates in a negative feedback
loop in the TGFβ signal transduction pathway [31]. Therefore, IFN-γ is thought to be an
antifibrotic  factor during tissue repair  that  can reduce synthesis  of  the extracellular  ma‐
trix  by disrupting signalling by the profibrotic  cytokine TGF-β [31,  32].  IFN-γ has been
found to influence skeletal muscle homeostasis and repair. In 1999 Shelton et al. reported
age-dependent  necrotizing  myopathy  in  a  transgenic  mouse  that  constitutively  overex‐
presses IFN-γ at the neuromuscular junction [33]. On the other hand, the administration
of  IFN-γ appears  to  improve the healing of  skeletal  muscle,  limit  fibrosis  and therefore
limit the function of a regenerating muscle [30]. In 2008, Cheng et al. showed that IFN-γ
is  expressed at  both  mRNA and protein  levels  in  skeletal  muscle  following injury,  and
that the time course of IFN-γ expression correlated with the accumulation of macrophag‐
es, T-cells, and natural killer cells, as well as myoblasts, in damaged muscle. The admin‐
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istration of an IFN-γ receptor-blocking antibody to wild-type mice impaired induction of
interferon response factor-1, reduced cell proliferation and decreased the formation of re‐
generating  fibres  [29].  In  2008,  Chen  et  al.  reported  a  synergistic  effect  of  IFN-γ  and
IGF-1,  which  is  known  to  have  beneficial  effects  on  muscle  regeneration  after  injury.
They showed that IFN-γ injected into injured muscle has the effect of anti-fibrosis, which
is  more  significant  than that  of  IGF-1.  They concluded that  a  combined injection could
improve muscle  regeneration,  while  inhibiting fibrosis  simultaneously,  and promote  the
healing  of  injured  muscle  [34].  Suramin,  an  antiparasitic  and  antitumor  drug,  acts  as  a
TGF-β inhibitor by competitively binding to the growth factor’s  receptor [35,  36].  It  has
been  evaluated  for  potential  clinical  applications  and  has  shown  antifibrotic  effects  in
chronic kidney diseases,  wound healing of  rabbit  conjunctiva and glaucoma after  trabe‐
culotomy [37, 38]. Chan et al. showed that suramin effectively inhibits fibroblast prolifer‐
ation and neutralizes the stimulating effect of TGF-β on the proliferation of fibroblasts In
vitro.  In vivo,  they showed that the injection of suramin two weeks after strain injury re‐
duces muscle fibrosis and enhances muscle regeneration, and thereby leads to improved
muscle strength recovery [39].  Although suramin can lead to side effects when adminis‐
tered intravenously,  local  intramuscular injection may not elicit  the same deleterious ef‐
fects  and  could  be  very  useful  in  improving  muscle  healing  [39].  Taniguti  et  al.
evaluated the effect of suramin on fibrosis in mdx mice, where TGF-β is highly unregu‐
lated  in  the  diaphragm  and  the  quadriceps  muscle.  Mice  received  suramin  for  seven
weeks while performing exercise on a treadmill  to worsen disease progression. Suramin
protected  limb  muscles  against  damage  and  reduced  the  exercise-induced  loss  of
strength  over  time.  These  findings  support  the  role  of  TGF-β  in  fibrogenesis  and myo‐
necrosis during the later stages of disease in mdx mice [40].
Relaxin, a polypeptide cytokine/growth factor, is a member of the insulin-like growth factor
(IGF) family. The historical role of relaxin has been in reproduction, in which it functions to
inhibit uterine contraction and induce growth and softening of the cervix. It can reduce type
I and type III collagen deposition, increase procollagenase synthesis, and, by doing so, re‐
duce fibrous scar tissue formation in many tissues [41, 42]. In an In vivo model of pulmonary
fibrosis, relaxin treatment dramatically decreased bleomycin-induced collagen content in the
lung, alveolar thickening, and improved the overall fibrosis score [43]. Recent studies using
the relaxin-null mouse model have demonstrated age-associated pulmonary fibrosis in these
animals that can be reversed by relaxin treatment [42]. In an innovative study, adenoviral-
mediated delivery of relaxin was used to treat cardiac fibrosis caused by transgenic overex‐
pression of the β2-adrenergic receptor, resulting in a dramatic decrease in interstitial
collagen content in the left ventricle, but not other (nonfibrotic) chambers of the heart [44].
In a recent study, Mu et al. injected relaxin intramuscularly into the injured site of the mouse
to observe its function In vivo. Results showed that relaxin promoted myogenic differentia‐
tion, migration, and activation of matrix metalloproteinases (MMPs) of cultured myoblasts
In vitro. Relaxin also promoted activation of muscle satellite cells and increased its local pop‐
ulation compared with non-treated control muscles. Meanwhile, both angiogenesis and re‐
vascularization were increased, while the extended inflammatory reaction was repressed in
the relaxin-treated injured muscle. [45]
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2.2. Platelet-rich plasma in muscle injury therapy
Among new therapeutic options for achieving more efficient healing, autologous thrombo‐
cytes have a very important place. Although there is no randomized prospective study con‐
firming its value, platelet-rich plasma as a source of autologous growth factors is thought to
be used by many sports physicians for treating muscle injuries. The use of platelet-derived
preparations was prohibited by WADA until 2011 but was removed from the list after con‐
sidering the lack of current evidence concerning the use of the method for the purposes of
performance enhancement as current studies did not reveal a potential for performance en‐
hancement beyond the therapeutic effect [46].
PrP (or platelet-rich plasma) may be defined as a volume of the plasma fraction of autolo‐
gous blood having a platelet concentration above the baseline [47]. Normal platelet counts in
blood range from 150000/µL to 350000/µL. Platelet-rich plasma contains a 3 to 5-fold in‐
crease in growth factor (GF) concentrations, sometimes more [47,48]. Platelet-rich plasma
can only be made from anticoagulated blood [47]. The process begins by adding citrate to
whole blood to bind the ionized calcium and inhibit the clotting cascade, followed by one or
two centrifugation steps to separate red and white blood cells from platelets. When using
anticoagulated PrP, activation is critical, as clotting results in the release of GF from the pla‐
telet α-granules (degranulation). PrP may be activated immediately before application, or it
can occur In vivo. There is no consensus on the timing of PrP activation, or even whether
activation is necessary at all [47]. Approximately 70% of the stored GF is released within 10
minutes, and more than 95% of the GF is released within 1 hour. Some GF is produced by
the platelets during the next 8 to 10 days. Originally, bovine thrombin was used as an acti‐
vating agent; however, a rare but major risk of coagulopathy from antibody formation has
restricted its use for activation. Calcium chloride (CaCl2) and autologous prepared thrombin
are now used for activation instead. The CaCl2 is added during the second centrifugation
step to form a dense fibrin matrix in which platelets are trapped and release GF. Soluble col‐
lagen type I may also be used for activation. It is important to note that the composition of
commercially derived PrP products differ qualitatively and quantitatively [49]. The most im‐
portant difference is in the concentration of platelets as well as in the concentration of leuko‐
cytes in the preparation. Whether leukocytes have a positive or negative role is not clear yet.
The paradigm suggests that neutrophils infiltrate injured tissue and in the process of assist‐
ing the removal of disrupted tissue, exacerbate or increase the original damage [49].
Platelet-rich plasma can potentially enhance healing by the delivery of various GF and cyto‐
kines from the α-granules contained in platelets. Platelets also contain subpopulations of α-
granules that undergo differential release during activation, a potentially important point in
understanding how PrP is activated and acts [47, 48]. Platelets contain, synthesize and re‐
lease large amounts of biologically active proteins that promote tissue regeneration. Re‐
searchers have identified more than 1100 types of proteins inside platelets or on their
surface [47-49]. The most commonly studied platelet proteins include platelet-derived
growth factor (PDGF), transforming growth factor (TGF-β), platelet-derived epidermal
growth factor (PD-EGF), vascular endothelial growth factor (VEGF), insulin-like growth fac‐
tor I and II (IGF-I, IGF-II), fibroblastic growth factor (FGF), and cytokines, including proteins
Current Issues in Sports and Exercise Medicine8
such as platelet factor 4 (PF4) and CD40L. The roles of the above listed growth factors are
listed in Table 2 [47, 48, 50].
Growth
Factor Target tissue/cell Function
FGF Blood vessels, smooth muscle, skin fibroblastsand other cells
Proliferative and angiogenic action Stimulates
collagen production
VEGF Blood vessels Stimulates vascularisation by stimulating vascularendothelial cells
TGF-β Blood vessels, skin cells, fibroblasts, monocytes Stimulates fibroblast production Stimulatesproduction of collagen type-I and fibronectin
PDGF A+B Fibroblasts, smooth muscle cells, chondrocytes,osteoblasts, mesenchymal stem cells
One of the first growth factors to be expressed
after injury
Stimulates other growth factor secretion Stimulates
angiogenesis and macrophage activation
Chemotaxic and proliferative action on fibroblasts,
stimulates collagen synthesis
PD-EGF Blood vessel, skin cells fibroblasts and other cells
Stimulates epidermal regeneration and wound
healing by stimulating keratinocytes and dermal
fibroblasts Promotes cell growth, recruitment,
differentiation
Stimulates cytokine secretion
IGF-I, II Bone, blood vessel, skin, other tissue fibroblasts
Chemotactic for fibroblasts
Stimulates protein synthesis
Enhances bone formation
PF-4 Neutrophils, fibroblasts Stimulates influx of neutrophils Chemotactic forfibroblasts
Myostatin,
Mainly function on bone/skeletal muscle
adaptation and repair
Leukaemia inhibitory factor (LIF),
mechano growth factor (MGF),
Bone morphogenetic protein (BMP)
(a member of TGF-β superfamily)
Table 2. Growth factors released from platelets and their function
In vitro studies showed that the application of PrP enhances gene expression of the ECM
proteins, has mitogenic activity, promotes tenocyte proliferation and induces secretion of
other growth factors [47]. Importantly, animal studies showed that all positive effects of PrP
Novel Therapies for the Management of Sports Injuries
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are neglected when no mechanical stimuli are applied to the tendon during the healing peri‐
od, e.g. if the tendon is immobilised. Besides increased expression of growth factors, PrP
was found to increase the expression of matrix degrading enzymes. PrP may also promote
antibacterial effects. In addition to opsonophagocytosis, chemotaxis, and oxidative microbi‐
cidal activity, platelets and leukocytes can release a variety of small cationic peptides (anti‐
bacterial peptides) that have bactericidal activity [47].
When treating ligament injuries with PrP, animal studies suggest that use of PDGF-BB may
improve the quality of healing medial collateral ligaments, and in a similar way PrP may
influence the healing of other ligaments [51]. The effect of PrP may be dose and time-related
[52]. However, extra-articular ligaments showed better wound site filling and increased the
presence of finbrinogen and GF when healing as compared to intra-articular ligaments (like
ACL), but the application of PRP can improve the results after ACL injury [53].
To date, no major adverse effects of PrP have been noted in humans. No adverse effects
were observed when PrP was infiltrated in 808 patients,  mainly with osteoarthritis  [54].
The use of  bovine thrombin for  activation may cause a  hypersensitivity  reaction and is
therefore  avoided in  modern preparation techniques  [47].  To date,  there  is  no  evidence
of a systemic effect of local PrP injection or carcinogenesis. The latter may be mainly due
to the short In vivo half-lives and local bioavailability of GF produced by PrP [47]. At the
moment,  PrP is  permitted by WADA (The World Anti-Doping Agency) by all  routes of
administration since 2011 [47].
The International Olympic Committee Consensus Statement expresses that current evidence
suggests the use of PrP to be safe. They proposed that what type of PrP product is used and
how it has been prepared, validated and tested should be made clear [47].
Suggested techniques for the application of PrP and post-injection recommendations of the
International Olympic Committee Consensus Statement are [47]:
1. PrP is considered to act best when placed at the site of injured tissue; therefore ultra‐
sound guidance is advisable for accurate needle placement to the injured site.
2. With respect to tendon administration, there is no agreement on whether the needle
should be placed inside the tendon or in the surrounding tendon sheath. In the pres‐
ence of exudates around the tendon, it is suggested that it be evacuated before PrP is
injected.
3. If PrP is administered at arthroscopy, it is suggested that the injection be administered
after emptying the joint of arthroscopic fluid. In the case of open surgery, the applica‐
tion of PrP can be undertaken using one of the gel or semi-solid forms.
4. Patients should follow general recommendations after an injection with rest, ice, and
limb elevation for 48 hours. Depending on the site of treatment and extent and duration
of the condition, patients may follow an accelerated rehabilitation protocol under ap‐
propriate supervision.
In the XX (number needed for chapter: physiology of sports injuries) chapter of this book, all phas‐
es of healing in an injured tissue are described. They are influenced by a number of growth
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factors that control cell functions through direct interactions with extracellular parts of the
transmembrane receptors. Because thrombocytes represent a major source of growth factors
in blood clots, the idea to concentrate them at the site of injury is well accepted. The effects
of several individual growth factors have been studied in muscle regeneration. Results from
In vitro studies are variable; however, their obvious role in regeneration is not to be neglect‐
ed. Growth factors together with macrophages and products of the cyclooxygenase 2
(COX-2) regulatory pathway regulate the inflammatory phase during regeneration in skele‐
tal muscle [55]. IGF-1 and FGF have been shown to have positive effects on healing and fast-
twitch tetanic strength in a murine model of muscle laceration [56]. In case of gastrocnemius
contusion, the local application of both GFs lead to higher satellite cell activation in bigger
muscle fibre development [57]. Despite the promising potential of PrP for treatment of mus‐
cle injuries, some doubts have arisen concerning their use. Due to application of exogenous
TGF-β into the tissue, which has been proven to be highly responsible for tissue scarring,
some experts are not defenders of this particular therapeutic option. However, in a recent In
vitro study using human myoblast cell lines it was shown that PrP-derived growth factors
promote satellite and muscle cell proliferation as well as inhibiting fibrotic differentiation,
mainly due to down-expression of TGF-β [58].
To date there are no randomized control studies confirming the real role of PrP in treating
muscle injuries [59], nor was any sample in clinical studies large enough to represent rele‐
vant statistical data [48]. However, the preclinical data seems to be promising enough for
clinical studies to take place.
2.3. Other bioactive agents to improve muscle healing
Manose-6-Phosphate  (M6P)  is  a  natural  inhibitor  of  TGF-β,  a  carbohydrate  molecule  with
structural similarity to TGF-β and has been shown to reduce its activity [2, 60]. In an ex‐
periment by Roberts et al.,  M6P reduced scarring in incision wounds in rats [61].  In an‐
other recent study M6P significantly reduced TGF-β1-mediated transformation of human
corneal  fibroblasts  into myofibroblasts  and is  therefore a  potential  modulator  of  corneal
wound healing that may reduce haze after refractive surgery [62]. Regarding the muscu‐
loskeletal  system, only a few studies on tendons had been performed to date.  In an ex‐
periment by Bates et al. the antifibrotic effect of M6P was under observation In vitro and
In vivo,  where primary cell  cultures from the rabbit  flexor tendon sheath,  epitenon,  and
endotenon were established and supplemented with TGF-β along with increasing doses
of M6P. They also transected and immediately repaired rabbit flexor tendons. M6P solu‐
tion  was  added to  the  repair  sites  and compared to  a  placebo group.  They found that
M6P  is  effective  in  reducing  TGF-β  upregulated  collagen  production,  which  correlated
with  the  finding  that  a  single  intraoperative  dose  of  M6P  improved  the  postoperative
range of  motion.  Because of  its  nonimmunogenic  property and because it  is  easily  pro‐
duced,  M6P  could  be  an  ideal  candidate  for  clinical  application  in  muscle  injuries  [2].
Yang et  al.  studied the effects  of  M6P on TGF-β peptide and receptor expression in or‐
der  to  provide  the  experimental  basis  for  preventing  tendon-healing  adhesion  by  M6P.
They found that M6P can significantly decrease the expressions of TGF-β peptide, TGF-β
Novel Therapies for the Management of Sports Injuries
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receptor, TGF-β mRNA and may therefore provide a means of modulating the effects of
TGF-β on adhesion formation in flexor tendon wound healing [63].
Although N-acetylcysteine  (NAC)  is  a  non-toxic  aminothiol  widely known as  an antidote
to  acetaminophen  overdose,  it  has  multiple  other  uses  supported  by  varying  levels  of
evidence,  like  chronic  obstructive  pulmonary  disease  exacerbation,  prevention  of  con‐
trast-induced kidney damage during imaging procedures,  and treatment  of  infertility  in
patients  with  clomiphene-resistant  polycystic  ovary  syndrome [64].  Recent  studies  have
emphasized the role of oxidative stress as the molecular basis of lung fibrosis. NAC has
a strong reductive capacity that inhibits the TGF-β-stimulated collagen production in cul‐
tured fibroblasts [65].  Moreover,  it  has been shown by Hagiwara et  al.  that the aerosol‐
ized administration  of  NAC attenuates  the  lung fibrosis  induced by  bleomycin  in  mice
[66]  suggesting  the  suppressing  effects  of  antioxidant  TGF-b1  signalling  In  vitro  and In
vivo.  A recent study demonstrated that NAC reduces the disulfide bonds of TGF-b1 and
changes the bioactive form to the inactive form [67]. It  also changes the binding activity
of TGF-b1 to its receptor in hepatic stellate cells, suggesting that the effect of antioxidant
NAC is based on a direct blockade of TGF-b1 function and signalling. However, whether
NAC can modulate the TGF-b1-induced tissue repair, mediator production, and differen‐
tiation in human lung fibroblasts has not been fully elucidated [68]. Sugiura et al. recent‐
ly  reported  that  NAC  affects  the  production  of  fibronectin  and  vascular  endothelial
growth  factor  (VEGF),  which  are  believed  to  be  important  mediators  of  repair  and  re‐
modelling. The effect of NAC on the TGF-β induces differentiation to myofibroblasts by
assessing a smooth muscle actin (a-SMA) expression [68]. Although treatment with NAC
has been shown to attenuate interstitial fibrosis in mouse models of hypertrophic cardio‐
myopathy mutation and several other pathological states [69], no studies have been per‐
formed on the effects of NAC in muscle regeneration after injury. However, since it has
been shown to have beneficial effects on diseases that share the same pathophysiological
core with the process of muscle fibrosis,  the effects of NAC could potentially be benefi‐
cial in this pathology as well. Because it is a safe, inexpensive, and well-tolerated antioxi‐
dant with a well-defined mechanism of action, a highly favourable risk/benefit ratio and
low rate  of  adverse  events  [64],  researchers  will  probably  study  the  effects  of  NAC in
muscle repair in the future.
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs)  have
also shown beneficial  effects  in  studies  of  muscle  healing.  ACE is  a  circulating enzyme
that participates in the body's renin-angiotensin-aldosterone system (RAAS), which mod‐
ulates extracellular volume and arterial  vasoconstriction.  Its  inhibitors reduce morbidity,
mortality,  hospital  admissions,  and decline in physical  function and exercise capacity in
congestive heart failure patients. These therapeutic effects are attributed primarily to ben‐
eficial  cardiovascular  actions  of  these  drugs  [70].  Observations  have  linked  pathologic
fibrosis in various organ systems to the local effects of angiotensin II. The modulation of
angiotensin  II  with  angiotensin-converting  enzyme  inhibitors  or  angiotensin  II  receptor
blockers  has  demonstrated  decreased  fibrosis  and  improved  function  in  liver,  kidney,
and lung tissue [71-74].  Injured cardiac muscle also demonstrates dysfunction related to
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fibrosis.  Myocardium  exposed  to  decreased  levels  of  angiotensin  II,  either  through  the
use of  ACE inhibitors or ARBs,  has also demonstrated a measurably improved function
[75, 76]. However, it has been suggested that ACE inhibitor-induced positive effects may
also be mediated by direct action on the skeletal muscle [70]. Recent studies reported on
the beneficial side effects of ACE inhibitors in hypertensive patients free of chronic heart
failure [70].  Treatment with ACE inhibitors was associated with better  performance and
muscular outcomes, and genetic studies also support the hypothesis that the ACE system
may  be  involved  in  physical  performance  and  skeletal  muscle  function  [77,  78].  More‐
over,  elite  athletes,  particularly those in endurance sports,  have also demonstrated find‐
ings  consistent  with  inherent  differences  in  their  body’s  metabolism  of  angiotensin  II,
with  decreased exposure  resulting  in  improved skeletal  muscle  function [70,  79,  80].  In
an In vitro and In vivo study by Bedair et al. angiotensin receptor blocker therapy signifi‐
cantly  reduced fibrosis  and led to  an increase in  the  number of  regenerating myofibres
in  acutely  injured skeletal  muscle  and may therefore  provide a  safe,  clinically  available
treatment for improving healing after skeletal muscle injury [81].
3. Future perspectives of cartilage tissue repair
Damage  to  articular  cartilage  is  of  great  clinical  consequence  since  the  cartilage  tissue
comprises of  limited intrinsic  potential  for  healing due to the lack of  blood supply and
subsequent  incomplete  repair  by  local  chondrocytes  with  inferior  fibrocartilage  forma‐
tion. Surgical intervention is often the only option, but the repair of damaged cartilage is
often  less  than satisfactory,  and rarely  restores  full  function  or  returns  the  tissue  to  its
native normal state.
Tissue engineering of articular cartilage still remains challenging due to the special structure
of cartilage tissue consisting of multiphasic cellular architecture and great weight-bearing
characteristics. Good knowledge and understanding of cartilage structure, its metabolism,
and the process of chondrogenesis enables In vitro cartilage production in terms of tissue en‐
gineering. The new concept of cartilage tissue preservation uses tissue-engineering technol‐
ogies, combining new biomaterials as a scaffold, the application of growth factors, the use of
stem cells, and mechanical stimulation. Scaffolds enable 3-dimensional environmental con‐
ditions to promote hyaline-like cartilage production. Additionally, various types of growth
factors, which are the endogenous regulators of chondrogenesis, can be applied locally or in
culture condition to promote cartilage development. Further studies are attempting to create
the ideal scaffold and explore the synergistic effect of concomitant application of growth fac‐
tors and mechanical loading. In clinical practice, new generations of autologous chondrocyte
implantation (ACI) are based on the use of biodegradable materials that serve as temporary
cell-carriers for the In vitro growth and subsequent implantation into the cartilage defect.
Moreover, single stage procedures appear attractive, as they consist of natural chondral tis‐
sue inserted on the carrier and can reduce cost and patient morbidity since they avoid sec‐
ond operation and cell culturing procedures.
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3.1. Tissue engineering of articular cartilage
The field of tissue engineering uses the principles of cell biology, engineering, and medi‐
cine in order to  produce such a construct  that  can successfully replace damaged tissue.
Engineered  tissue  should  comprise  of  the  characteristics  of  the  native  intact  tissue  in
terms  of  histological  structure,  morphology,  function,  and  mechanical  properties.  The
challenges of tissue engineering of articular cartilage include isolating and culturing cells
to gain relevant and reproducible constructs with good durability In vivo.  A demanding
and crucial  role  in  the  process  of  In  vitro  culturing represents  phenotype regulation,  In
vitro  expansion,  scaffold  design,  the  use  of  bioreactor,  etc.  All  of  these  components
should be optimized to advance cartilage tissue engineering from culturing to clinical ap‐
plication. In particular, there is still a need to develop suitable scaffolds that can provide
a 3-dimensional  environment for the cell  to adhere to and adequately proliferate.  Addi‐
tionally,  scaffolds should be mechanically strong and biocompatible.  Cartilage tissue en‐
gineering  usually  uses  bioactive  molecules  (growth  factors)  and  mechanical  loading  to
promote differentiation towards a cartilage phenotype [82].
3.1.1. Biomaterials and scaffolds
Scaffolds are engineered extracellular matrices that serve as an artificial structure capable of
supporting 3-dimensional tissue formation. Cells are often implanted or seeded into these
scaffolds and different biomaterials are used that allow cell attachment, growth, differentia‐
tion, and regeneration of functional cartilage tissue. Scaffolds were developed with the aim
to improve the biological performance of chondrocytes as well as render the surgical techni‐
que easier. In cartilage tissue engineering, scaffolds should comprise of the following char‐
acteristics; they should be biocompatible (not triggering inflammatory response and not
toxic), offering temporary support to cells, mechanically strong to protect cells and with‐
stand In vivo forces during joint movement, and bioactive to provide cellular attachment and
migration. Additionally, scaffolds should be biodegradable, serving as a temporary con‐
struct that is later replaced by a newly synthesized extracellular matrix (ECM) [83]. With
time, the transplanted chondrocytes take over the function of the cell carrier; therefore they
should be degraded once they have served their purpose. The ideal biodegradable scaffold
should also enable uniform cell spreading possible [84-87].
In general, scaffolds are divided into natural material, synthetic polymers, and new materi‐
als. Natural materials include collagen, hyaluronic acid, fibrin glue, chitosan, agarose, and
alginate. Their advantage is excellent biocompatibility since they are natural bodily constitu‐
ents, thus degradation is physiological and non-toxic. On the other hand, their use includes
sourcing, processing, and the risk of disease transmission. Synthetic polymers, especially
PLA (poly alfa-hydroxil acid polymers) and PLGA (poly lactic-co-glycolic acid) are also widely
used due to the approval of the FDA. Their major advantage is the design flexibility (highly
porous 3-dimensional structure) and no risk of disease transmission. The disadvantages are
acid degradation products, inflammatory response, and chronic inflammation due to high
molecular weight proteins. Novel materials have been introduced recently, such as silk, cel‐
lulose, and other synthetic materials (biodegradable elastomer, polycaprolactone, poly
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(ether ester) copolymer scaffolds). Additionally, the combination of different materials is ap‐
plied [88], e.g. gelatin and hyaluronic acid have been combined with a fibrin glue and chon‐
droitin-6-suplphate. Furthermore, scaffolds to support bone formation (hydroxiapatite)
were combined with the chitosan to enable the regeneration of osteochondral lesions.
The new approach represents the development of smart matrices that actively support carti‐
lage formation and not only provide mechanical function but also allow control over cell
metabolism, tissue formation, enable adjustment of the physical properties, inclusion of
ECM motifs and active substances such as GF incorporated in microspheres to allow tempo‐
rally and spatially controlled delivery of GF in scaffolds [87].
Although most of these developments seem to be promising for future clinical application,
they are mainly used In vitro and in animal models [84-87]. Chondrocytes previously ex‐
panded and seeded onto scaffold produce a characteristic ECM rich in proteoglycans, colla‐
gen type II and aggrecan. After implantation in the full thickness femoral defect in rabbits, it
promoted healing and regenerated a cartilage-like tissue [89]. The future prospective for car‐
tilage repair is also based on the quality of integration between the newly formed tissue and
the native tissue for achieving stable healing.
3.1.2. Growth factors
Growth factors and their signaling pathways are the essential regulators of chondrogenesis dur‐
ing tissue engineering and thus are the prime candidates for engineering of cartilage tissue.
Chondrogenesis is a multistep process that comprises of several steps: precursor cell condensa‐
tion, differentiation towards chondrogenic phenotype, secretion of cartilage specific ECM com‐
ponents (collagen type II, aggrecan and others), chondrocytes proliferation in the area of growth
plate, further differentiation towards hypertrophy, and replacement of cartilage with the bone
tissue. All of the steps are regulated by different and overlapping signals (Figure 1).
Figure  1.  Schematic  diagram  of  different  stages  of  chondrogenesis  (including  main  growth  factors  and  altera‐
tions in ECM)
Novel Therapies for the Management of Sports Injuries
http://dx.doi.org/10.5772/53593
15
In general, GFs are endogenous regulators of chondrogenesis and their logical choice of use
appears to be promising to stimulate anabolic responses and the repair of articular cartilage.
For example, in In vitro cartilage formation it is essential to promote early chondrocytes dif‐
ferentiation and proliferation while trying to prevent further differentiation towards hyper‐
trophy. However, the design and optimization of all GF’s for a particular tissue engineering
and/or local application is complex and has to consider the combination of different factors,
their timing, concentrations, etc.
The most important factors currently used in tissue engineering are the members of trans‐
forming growth factor β (TGF-β) family, Bone Morphogenetic Protein (BMP), Insulin-like
growth factors (IGF), Fibroblast Growth Factors (FGF), especially FGF-2 and FGF-18, Epider‐
mal Growth Factor (EGF) and Vascular-Endothelial Growth Factors (VEGFs). The summary
of the effect of different GFs on chondrocytes/cartilage is presented in Table 4. It is becoming
increasingly apparent that GFs work synergistically and simultaneously to induce and pro‐
mote cartilage formation; e.g.: TGF-β1 and FGF-2 [90] together with IGF-1 [91], BMP-7 and
IGF-1 [91], TGFβ3 and BMP [92], etc. Based on the concept that several different GFs work in
combination during cartilage repair, the use of PrP, autologous conditioned serum (ACS),
and bone marrow concentrate were used in cartilage repair techniques [93].
Growth factors Effect on chondrocytes/cartilage
TGF-β Transforming Growth Factor β Stimulates synthesis of ECM Decreasescatabolic activity
BMP-2 Bone Morphogenetic Protein - 2 Stimulates synthesis of ECM Increased ECMturnover (increased aggrecan degradation)
BMP-7 Bone Morphogenetic Protein - 7 Stimulates ECM synthesis Decrease cartilagedegradation
IGF-1 Insulin-like growth factors Stimulates ECM synthesis Decreases matrixcatabolism
FGF-2 Fibroblast Growth Factors-2 Decreases aggrecanase activity Antagonizes PGsynthesis
FGF-18 Fibroblast Growth Factors-18 Increases chondrocyte proliferation andstimulates ECM
Table 3. Proven effects of various growth factors on cartilage
3.1.3. Mesenchymal stem cells
Mesenchymal stem cells (MSCs) are pluripotent cells found in multiple human adult tissues
including bone marrow, synovial tissues, and adipose tissues. They are of great interest for
scientists involved in cell therapy and tissue engineering since they have self-renewal ca‐
pacity and multilineage differentiation potential. Depending on the cultivation conditions,
they can differentiate into adipogenic, ostegenic or chondrogenic cells as well as form bone,
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cartilage, and fat. Currently, researchers are exploring the possibilities of manipulating the
stem cells under laboratory conditions into mature chondrocytes that can then be integrated
into scaffolds for later application [94,95]. There are many studies reporting the isolation
and characterization of MSCs from adult human synovium and periosteum and providing
evidence about their multipotency at the single cell level [96, 97]. It was also demonstrated
that human MSCs from different tissues possess distinctive biological properties [98]. Addi‐
tionally, there is still the issue of whether MSCs are capable of forming stable hyaline-like
cartilage as opposed to that formed during the process of endochondral ossification, which
is later replaced with bone. The variability in biological responses of MSCs and no standar‐
dized MSC bioprocessing to obtain MSC preparations with consistent, reproducible, and
quality-controlled biological potency for therapeutic applications limit the use of MSCs in
clinical practice. On the other hand, the use of MSCs as chondrocyte substitutes in an ACI-
equivalent procedure has become highly attractive since MCSs are easily accessible, easy to
isolate and capable of expanding into culture as opposed to articular chondrocytes with lim‐
ited proliferative capacity and rapid de-differentiation In vitro.
Furthermore, MCSs appear to be immune privileged under certain conditions [94-97]. Alto‐
gether, these properties would allow the generation of large batches of quality controlled
MCSs preparations ready for allogenic use. In addition, limitations in patient-to-patient vari‐
ability would be circumvented [93]. In animal models, MSCs have already shown significant
potential for cartilage repair and novel approaches using MSCs as an alternative cell source
to patient-derived chondrocytes are being tested [89, 99]. However, preclinical and clinical
studies should be conducted in order to evaluate whether the implantation of MCSs results
in a cartilage formation that is as durable as the one following the implantation of articular
chondrocytes. Additionally, the application of MCSs can be further expanded to non-local‐
ized chronic lesions in osteoarthritis patients [100].
3.1.4. Mechanical load
A potential strategy in cartilage functional tissue engineering comprises of the effect of me‐
chanical stimuli applied during In vitro tissue formation. Several studies demonstrated that
mechanical forces stimulate the synthesis of ECM and may even enhance the mechanical
properties of the developing tissue [101, 102]. After physical stimuli are applied to the tissue,
the intracellular mechanisms convert mechanical signals into biochemical events responsible
for regulating the transcription of genes governing cell growth and differentiation. This ef‐
fect proved to be further intensified with concomitant application of growth factors and me‐
chanical load in a synergistic manner [103, 104]. Various bioreactor systems have been
developed in order to form cartilaginous grafts with similar biomechanical characteristics
compared to native intact cartilage tissue [105-107]. Due to the complexity of the load and
motion patterns within an articular joint, new bioreactors with multi-axial loading patterns
are designed to recreate the In vivo situation [106, 107]. The interesting aspect of cartilage re‐
pair in clinical practice represents cell-based strategies that are not culture-intensive and al‐
low single surgical procedure. Hence, a natural environment is the most suitable for tissue
development therefore cell culture and bioreactors may not be required [108].
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3.2. Clinical application of tissue engineering in cartilage repair
Cartilage repair has gained great interest since autologous cartilage implantation (ACI) has
become an established treatment. The first line of treatment options remains microfractur‐
ing, due to low cost, arthroscopic procedure, and ease of performance.
Bone marrow stimulation techniques as well as ACI represent the cell-based approach for
tissue regeneration in which the attendance of specific cells with the ability of proliferation
and differentiation in desired cell phenotype plays a crucial role. In the case of bone marrow
stimulating techniques, these cells are recruited from the bone marrow either by drilling or
microfracturing; as such they are released from the medullar canal and subsequently form
the blot clot on the side of the lesion. However, the final result is fibrous cartilage with infe‐
rior biomechanical properties compared to native hyaline cartilage. On the other hand, the
histological analysis of random biopsy specimens after ACI procedure indicated the pres‐
ence of type-II collagen and hyaline-like cartilage within the healing tissue.
ACI is both technically demanding and associated with a high percentage of reoperations.
The modification of this cell therapy was designed to reduce complications such as perios‐
teal hypertrophy, the need for second look arthroscopy, the development of fibrocartilage
tissue with variable amount of hyaline cartilage, etc. The next generation of ACI was devel‐
oped by replacing the periosteal patch with a biocompatible matrix and selecting cells of po‐
tentially improved chondrogenic potential. For example, second generation ACI uses
collagen-covered autologous cultured chondrocyte implantation and in third-generation
ACI, special cell carriers or cell-seeded scaffolds were created. Fourth generation cartilage
repair focuses on growth factors and gene therapy, the use of stem cells and tissue engineer‐
ing [109, 110]. In general, arthrotomy and a two-stage procedure are the most commonly
used, but all-arthroscopic techniques and one-stage procedures (e.g. technique with minced
articular cartilage) have become highly attractive treatment techniques. Additionally, pre-
implantation chondrocyte phenotype manipulation has also shown excellent outcomes.
3.2.1. Second generation ACI
Second generation ACI is still a two-step procedure, but in contrast to classical ACI it involves
culturing in 3-dimensional conditions, which favours the maintenance of phenotypic stability
of chondrocytes. In particular, chondrocytes are cultured on the scaffold that is biocompatible,
enables cellular growth, and as such represents the graft to be transplanted. These scaffolds/
matrices containing the chondrocytes are implanted on the chondral lesion and attached with
fibrin glue. In this manner, periosteal grafts and their suturing onto healthy cartilage are not
necessary. These techniques were developed in an attempt to resolve some of the most com‐
mon problems indicated by the standard ACI technique such as periosteal hypertrophy, which
is a source of complaints about localized pain among some patients.
The scaffolds used in second generation ACI should comprise all of the following futures: bio‐
compatibility (no inflammatory response), biodegradability (controlled rate of degradation),
bioactivity (promote maintenance of phenotype and proliferation), and permeability (to en‐
sure nutrition). Natural and synthetic scaffolds can be used. The concern about the synthetic
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scaffolds is the risk of the harmful effect of degradation products on surrounding tissue. A
comparison of the first and second-generation ACI has shown rather equivalent short-term
clinical outcomes, with similar complications and a similar rate of reoperation [110]. A variety
of scaffolds have been introduced, implanted either through a small arthrotomy or arthroscop‐
ically and will be presented briefly: collagen-covered ACI (CACI or ACI-C), Hyalograft C
based on hyaluronic acid and membrane/matrix induced ACI (MACI) and others.
The main innovation in CACI is the use of bioresorable collagen membrane cover instead of
the periosteal cover. Initial reports showed clinical improvements of this second generation
ACI with fewer complications compared to classical ACI. The clinical and functional assess‐
ment after two years showed that 74% of patients had good or excellent results following
CACI compared to 67% after classical ACI (ACI-P or PACI – periosteal ACI). Revision ar‐
throscopy was required in 36.4% in the PACI group one year after surgery due to shaving
for hypertrophy compared to none in the CACI group [111]. In the systemic review of ACI
procedures including 82 studies they reported that the failure rate was highest in PACI
(7.7%) compared to CACI (1.5%). Similarly, the highest rate of unplanned re-operation was
in the PACI group (27%) compared to CACI (5%) [112].
Matrix-induced ACI (MACI) was first introduced in 1998. In this technique, cells are seeded
directly onto the surface of a biodegradable type I/III collagen membrane and as such over‐
come the shortcomings of the original periosteum-covered technique. The membrane is a bi-
layer structure, smooth on one side and rough and more porous on the inner side, with
incorporated cells to stimulate cartilage matrix specific molecules. It was shown that chon‐
drocytes can adhere and maintain their phenotypic characteristics while seeded onto a type
I/III collagen membrane [113]. The procedure requires limited exposure of the joint ensuring
shorter operation time and less morbidity. The rate of failure was low (0-6.3%) and mainly
due to symptomatic graft hypertrophy or detachment. However, clinical, arthroscopic, and
histological outcomes are comparable for CACI and MACI [114]. Additionally, MACI was
also significantly more effective after two years compared to microfracturing [115]. Al‐
though significantly improved results after 5 years were reported, MACI still remains the
cost-intensive alternative [116].
Hyalograft C implants autologous cells onto an esterified hyaluronic acid scaffold. It was re‐
ported that 76% of patients had no pain and 88% had no mobility problems. Additionally,
96% of patients’ treated knee was assessed to be normal by the surgeon and cartilage repair
was graded arthroscopically as normal or nearly normal in 96%. The majority of second-
look biopsies showed hyaline-like cartilage and a very low rate of complications were re‐
corded [117]. Several other studies also reported positive clinical results with Hyalograft C
[118, 119]. Similarly, in two comparative studies, researchers found superiority over hyalur‐
onic-acid based chondrocytes transplantation at five years follow up in respect to microfrac‐
ture in young, active patients [120, 121].
3.2.2. Third and fourth generation ACI
Recently, further technological advances have led to a third-generation ACI, where chon‐
drocytes are embedded into three-dimensionally constructed scaffolds (i.e. 3-dimensional
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environment) for cell growth [122]. This novel approach uses: chondro-inductive or chon‐
dro-conductive matrix; autogenous or alogenous cells treated In vitro in order to induce cell
proliferation, differentiation and production of ECM; a single-stage surgical approach; and
mechanical stimulation to improve the material properties and maturation of the implant
[123]. Such mature tissue might ensure shorter rehabilitation and shorten the time to achieve
clinical efficiency. For example, the DeNovo Engineered Tissue (ET) graft (Zimmer, War‐
saw) is generated from juvenile cartilage cells under special laboratory conditions and is
hyaline-like. It is engineered by ISTO Technologies and the FDA approved ISTO’s Investiga‐
tional New Drug (IND) application for Neocartilage in 2006, which allowed them to pursue
clinical trials of the product in humans.
Likewise,  Neocart  (Histogenics,  Waltham,  MA),  a  bioengineered tissue  patch containing
an autologous chondrocyte population matured in a biodegradable collagen matrix, uses
bioreactor technology (hydrostatic pressure with modified flow rates and low oxygen) to
stimulate ECM accumulation and suppress long-term degradation.  A recent randomized
study suggests that the safety of autologous cartilage tissue implantation, with the use of
the NeoCart technique is similar to that of microfracture and associated with greater clin‐
ical  efficacy  at  two  years  after  treatment  [124].  However,  there  are  still  technical  prob‐
lems  remaining  regarding  the  initial  fixation  technique,  subchondral  and  edge
integration, long-term durability, etc. [125].
A number of new generation ACI methods for implanting cultured autologous chondro‐
cytes in a biodegradable matrix are currently in development or testing. These include
Chondroselect (characterized chondrocyte implantation, TiGenex, Phase III trial), BioCart II
(ProChon Biotech, Phase II trial), Cartilix (polymer hydrogel, Cartilix), MACI® (matrix-in‐
duced ACI, Verigen, available outside of the U.S.), Cartipatch (solid scaffold with an agar‐
ose-alginate matrix, TBF Tissue Engineering, Phase III trial), NeoCart (ACI with a 3-
dimensional chondromatrix, Histogenics, Phase II trial) and Hyalograft C (ACI with a
hyaluronic acid-based scaffold, Fidia Advanced Polymers). Although the clinical use of
these second-generation ACI products has been reported in Europe, none are approved for
use in the U.S. at this time [126].
The future of fourth generation cartilage repair focuses on gene therapy, the use of stem
cells (bone marrow, adipose, or muscle derived) and tissue engineering. MSCs are an attrac‐
tive cell source due to their differentiation capacities. To expand and deliver MSCs to the
site of defect, the cells should be seeded into an appropriate scaffold that is biocompatible,
mechanically stable, permeable, and biodegradable. A variety of biomaterials were intro‐
duced, e.g. carbohydrate polymers (hyaluronan, agarose, alginate, PLA/PLGA) that are pro‐
tein-based (collagen, fibrin, gelatin) in order to obtain homogenous distribution within a 3-
dimensional matrix.
Future generations of cartilage tissue engineering will also include methods to control the
genome to direct chondrogenic differentiation towards a hyaline-like pathway. In this man‐
ner, the local cellular environment can be coordinated by a tightly regulated GFs that signal
molecules to regulate cellular maturation and proliferation. Additionally, with the use of
gene therapy, either viral or non-viral vectors can be applied into cells, which then express
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chondrogenic GF. Gene transfer enables localized exposure of bioactive proteins or gene
products to the site of tissue lesions. There have been numerous cDNAs cloned and used for
biological stimulation of cartilage healing in terms of mitosis induction, synthesis of ECM
components, induction of chondrogenesis by progenitor cells, inhibiting inflammatory re‐
sponse, etc. Researching involves identification and specific gene combinations that could be
incorporated into vectors and delivered to target cells [127]. Current data indicates that effi‐
cient delivery and expression of certain genes may have an effect on overall healing re‐
sponse in cartilage tissue and is capable of turning the repair response towards the synthesis
of a more hyaline cartilage tissue [128]. The novel approach in cartilage tissue engineering is
the use of cell population certification (screening of gene markers, positive and negative fac‐
tors, gene expression score - ChondroCelect), which enables prediction of whether cells are
capable of making stable hyaline-like cartilage In vitro. By selecting those characterized cells
with a high probability of maintaining a chondrogenic phenotype, the effectiveness of trans‐
planted chondrocytes would be maximized.
3.2.3. One-step surgery
Recent directions in cartilage repair are moving towards the possibility of performing one-
step surgery, including the use of MCS and GF, and to avoid the first surgery, harvesting
cell material, and subsequent cell cultivation. Numerous studies reported that bone marrow
stem cells are a useful source for restoring cartilage defects. Additionally, by the concomi‐
tant use of PRP and MCS it is possible to develop a single step procedure.
Single stage procedures can be divided into two categories: cell free implants (scaffolds) and
cell-based implants (further subdivided according to the cell type utilized; auto- and allog‐
rafts). One of the most common cell-free procedures is AMIC (autologous matrix-induced
chondrogenesis). The technique requires a cell free implant that is “smart” enough to pro‐
vide the appropriate stimuli to induce orderly and durable tissue regeneration. Moreover, it
should be capable of inducing in situ cartilage formation. The AMIC procedure comprises of
microfracturing combined with the implant of a porcine collagen type I/III bilayer matrix to
stabilize blood clot formation.
The first reports on the AMIC technique were promising and the results were comparable to
standard ACI with the advantage of a single stage technique and no donor site morbidity
[129]. In a study with the mean follow up rate of 37 months, they reported highly satisfacto‐
ry results in 87% with MRI showing moderate to complete filling and normal to hyperdense
signal [130]. Another possibility is to use bone marrow concentrate (BMC) for MCS in treat‐
ing cartilage defects. The technique consists of harvesting 40-60ml of bone marrow aspirate
from the iliac crest, centrifugation, and the use of special enzymes to activate the BMC and
produce the sticky clot material that is placed on the side of the lesion; finally the defect is
covered with a collagen membrane.
An attractive option in terms of cell-based technologies is represented by minced articular
cartilage procedures for repairing articular cartilage, as they are one-staged, autologous and
inserted on scaffold carriers that provide chondro-milieu, mechanical protection and even
distribution of the cells within the defect. The principle of the minced cartilage procedure is
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to obtain hyaline-like “minced” cartilage pieces supplemented with the scaffold delivery
system. Minced cartilage represents the source of cells and even relatively large defects can
be treated with a small amount of cells; specifically, one-tenth of the cartilage that originally
covered a defect is required. The proposed advantages of this procedure over conventional
treatment are the elimination of the need for in-vitro cell expansion and a second surgical
procedure. Several technologies are being investigated and are in current late stage trials
[131]. The autograft cell-based procedure CAIC (Mitek, USA) is currently under phase III
evaluation. During the procedure, autologous cartilage is harvested with the special shaver
device, then morcellized and secured on resorbable polymer mesh with fibrin glue. DeNovo
NT Graft (“Natural Tissue Graft”, Zimmer, Warsaw) is a similar application used for treat‐
ment of the cartilage lesions limited to an articular surface with intact subchondral bone. It
utilizes morcelized juvenile cartilage, which is secured with the fibrin glue. As there is no
use of chemicals and minimal manipulation, a DeNovo NT Graft does not require FDA ap‐
proval and is currently available in the United States. Both CAIS and DeNovo NT techni‐
ques rely on chondrocytes migration out of the cartilage tissue with subsequent matrix
production to fill the defect [130-132]. Early animal and preclinical models have demonstrat‐
ed hyaline-like cartilage. Clinical experience is limited, with short-term studies demonstrat‐
ing both procedures to be safe, feasible, and effective, with improvements in subjective
patient scores, and with magnetic resonance imaging [133].
4. Strategies to improve ligament and tendon repair
Tendons and ligaments are avascular and hypocellular with distinct mechanical features
that make them difficult for currently available treatments to reach a complete functional re‐
pair of the damaged tissue. Tendon injuries, whether acute or chronic, are commonly man‐
aged either conservatively or surgically. Conservative management, such as rest,
corticosteroid injection, orthotics, ultrasound, laser treatment, or shockwave provide pain
relief but, when they fail, surgery is required [134].
Surgical repair may be indicated in acute injuries. In chronic lesions, excision of the involved
area might be performed. However, repaired tendons have inferior properties when com‐
pared to healthy ones. The loss of mechanical features is mainly due to a distorted extra cel‐
lular matrix (ECM) composition and a misalignment of collagen fibrils of the scar tissue
[134]. Another option is to use tendon or ligament grafts, but graft-augmentation devices
and artificial prostheses have also been developed [135]. Because current treatment is subop‐
timal, alternative therapies have been developed, such as the delivery of growth factors, the
development of engineered scaffolds or the application of stem cells.
4.1. Grafts and graft-augmentation devices
Autografts are used widely to repair the affected tendon and prevent instability due to the
damaged ligament. The most commonly used autografts include hamstring tendons (semite‐
ndinosus and gracilis) and bone-patellar ligament (middle third)-bone. Several factors are
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important in the selection of the graft tissue reconstruction, such as the initial mechanical
properties of the graft tissue, morbidity resulting from graft harvesting, graft healing, and
the initial mechanical properties of the graft fixation, [134].
Allografts represent an alternative option to autografts for tendon and ligament repair. Be‐
cause of high cost, limited accessibility, associated risk of disease transmission and tissue re‐
jection with the use of allografts, autografts are preferred.
Immediately  after  a  reconstruction  with  autograft  or  allograft,  the  fixation  site,  not  the
graft  midsubstance,  is  considered  to  be  the  weakest  point;  following  that  period,  the
process  of  ligamentization  influences  the  mechanical  properties  of  the  graft,  making  it
more vulnerable.
To prevent  injuries  of  the  graft  until  integration  into  the  bone and the  process  of  liga‐
mentization is complete, graft augmentation devices were developed to provide immedi‐
ate  post-surgical  protection.  They share  mechanical  loads  with  the  biological  graft  until
the graft itself is capable of withstanding local tensile and compressive forces [134]. Graft
augmentation devices should be resorbable,  but the rate of resorption should be limited
by gradual transfer of mechanical loads to the biological graft [134, 135].
4.2. Tissue engineering
Tissue  engineering  (TE)  combines  biological  materials  and  cells  into  a  construct  that  is
eventually  able  to  replace  the  regenerated  tissue  [136],  through  the  merging  of  three
areas: scaffold microenvironment, stem cells,  and signalling biofactors. The goal is to re‐
construct a ligament/tendon by providing a scaffold seeded with cell-inducing neotissue
formation  that  adequately  meets  the  required  biological  and  mechanical  properties
[136,137]. Engineering fibrous tissues, such as tendons and ligaments, requires the use of
fibre-based  scaffolds,  because  they  should  possess  appropriate  mechanical  properties  to
withstand high stresses, but also high porosity and surface area to allow the seeded cells
to proliferate and regenerate the tissue [137].
4.2.1. Stem cells and scaffolds
The purpose of TE with responding cells is to induce a regenerative response instead of scar‐
ring. Tissue engineering can be divided into two subtypes: the In vivo approach and the ex
vivo-de novo. The In vivo approach permits the self-regeneration of small tissue lesions [138].
The ex vivo-de novo approach is designed to produce functional tissue that can be implanted
in the body. Several cells have been used: tenocytes, fibroblasts and stem cells. The latter can
be derived from bone marrow, human tendons (ACL, PCL), adipose tissue or embryonic de‐
rived stem cells [138].
Upon injury, elongated fibroblast cells resident in the tendon are activated by the inflamma‐
tory response for collagen deposition. To conduct this function, tenocytes are assisted by
tendon-derived stem cells (TDSCs) [139].
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MSCs do not differentiate spontaneously during In vitro culture, which permits a controlled
microenvironment, such as to dictate the differentiation of MSCs after implantation. Because
they are more easily isolated and banked from bone marrow compared to TDSCs, they rep‐
resent a more optimal source of stem cells suitable for therapeutic use. MSCs have been in‐
duced to differentiate to tenocytes through the Wnt signalling pathway and cyclic
mechanical stimulation that mimics normal processes [140]. It was also found that platelet-
rich plasma (PrP) stimulates both MSCs and TDSCs [139].
Adipose-derived stem cell (ASC) use for tendon regeneration and repair has recently been
taken into consideration. In a recent study, the role of these stem cells in primary tendon
healing has been investigated by a local autologous ASC-mixed platelet-rich plasma (PrP)
application at the site of tendon injury in a control to PrP application only [141]. The tensile
strengths experimental groups were found to be significantly higher in comparison to the
control group and, along with higher expression of collagen type I, FGF and VEGF levels in
the experimental group, ASCs seems to enhance primary tendon healing.
It  is  now  well  accepted  that  seeded  grafts  vastly  improve  outcomes  over  un-seeded
grafts.  Recently,  collagen  matrices  cultured  with  MSCs  have  appeared  on  the  horizon
for  tendon  repair  [142-144].  The  isoelectric  focusing  technique  aligns  collagen  fibres  to
the  parameters  of  the  target  tissue,  adjusting  the  density,  alignment,  and  strength  of
dense  connective  tissue  (Gurkan:  Comparison  of  morphology,  orientation,  and  migra‐
tion  of  tendon  derived  fibroblasts  and  bone  marrow  stromal  cells  on  electrochemically
aligned  collagen  constructs  2010).  These  matrices  support  a  higher  proliferation  rate  of
MSCs  compared  to  randomly  oriented  collagen.  Currently,  the  versatility  of  synthetic
polymers  shows  great  promise  in  tissue  engineering.  Poly  (1.8  octanediol-co-citrate)
scaffold (POC) is  a  highly reproducible  elastomeric  material  capable of  being used as  a
synthetic  scaffold  to  support  cell  growth.  Instead of  attaching  tendinous  grafts  to  bone
via  screws,  the  optimal  approach  is  reconstruction  using  the  collaboration  of  synthetic
materials  with  MSCs.  Paradoxically,  the  very  complexity  of  the  fibrocartilage  interface
makes  it  a  perfect  candidate  for  POC utilization.  A scaffold  with  three  distinct  regions
would  allow  formation  of  a  collagenous  tendon  along  one  edge,  osseous  material
along  the  other,  and  a  middle  zone  representing  the  transition  from  tendon  to  bone.
Given  the  capacity  of  MSCs  to  differentiate  into  osteogenic  and  tenogenic  lineages,  a
single  cell  population seeded onto  the  scaffold  could regenerate  the  complex  fibrocarti‐
lage interface.  Additionally,  POC scaffolds  could be crafted according to  the target  ten‐
don  interface,  relying  on  Wolff's  Law  to  govern  the  dynamics  and  load  of  the  tendon
aimed for  reconstruction [139].
4.2.2. Bioreactors
A bioreactor in TE is a device that simulates a physiological environment in order to pro‐
mote cell or tissue growth In vivo. Tendons respond to mechanical forces by changing the
metabolism as well as their structural and mechanical properties. Without the appropriate
biomechanical stimulation, newly formed tissue will lack appropriate collagenous organiza‐
tion and alignment for sufficient load-bearing capacity [134, 145, 146]. When subjected to
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mechanical stimulation In vitro, embryonic stem cells exhibited tenocyte-like morphology
and positively expressed tendon-related gene markers, as well as other mechanosensory
structures and molecules (cilia, integrins and myosin). In ectopic transplantation, the TE ten‐
don under In vivo mechanical stimulus displayed more regularly aligned cells and larger
collagen fibres that enabled enhanced tendon regeneration in situ, as evidenced by better
histological scores and superior mechanical performance characteristics [145]. In a recent
study, rabbit flexor tendons were deprived of cells and exposed to cyclic strain in a bioreac‐
tor, in comparison to a control, which was kept unloaded in a medium for 5 days [147]. The
tendons were then implanted to bridge a zone II defect in the rabbit, followed by determina‐
tion of ultimate tensile strength and elastic modulus after 4 weeks. Both were significantly
improved in tendon constructs that were exposed to cyclic strain, and the histology showed
an increased cellularity in the bioreactor tendons. In another study, it was showed that the
material properties of human allograft tissue-engineered constructs can be enhanced by re‐
seeding and dynamic conditioning [148]. It was found that while conditioning duration has
a significant effect on material properties, the load magnitude does not. The issue of attrition
in biomechanical properties with time following cycle completion must be addressed before
bioreactor preconditioning can be successfully introduced as a step in the processing of
these constructs for clinical application.
4.2.3. Growth factors
Following acute tendon injury, circulation-derived cells play a crucial role in the healing
processes of tissue. It was shown, that locally injected PrP is useful as an activator of circula‐
tion-derived cells for the enhancement of the initial tendon healing process [149]. PrP also
improves the mechanical properties of tendons in the early phase following acute injury, in
terms of increase in the force at failure, ultimate stress, and stiffness; but the effect seems to
vanish in the long-term follow up [150]. To date, there is still a debate regarding the positive
effect of PrP following acute tendon injury. There are studies that confirm the positive effect
of PrP on tendon healing, since an earlier return to sports, decreased cross-sectional area of
tendon, and improved earlier range of ankle motion, following Achilles tendon reconstruc‐
tion was noted [151]. It is speculated that In vivo use of PrP, as well as platelet-poor plasma
to a certain extent, in tendon injuries might accelerate the catabolic demarcation of traumati‐
cally injured tendon matrices and promote angiogenesis and formation of a fibrovascular
callus [152]. A study showed that platelets influence only the early phases of regeneration,
but this allows for mechanical stimulation to start driving neo-tendon development at an
earlier time point, which kept it constantly ahead of the controls [153]. However, all studies
do not confirm the positive effect of PrP; in fact a possible negative effect of PrP on the func‐
tional results after the reconstruction of an Achilles tendon during a long-term follow up
was observed [154].
In chronic tendon lesions, especially tendinopathy, the use of PrP is focused on restoring
normal tissue composition while avoiding further degeneration. Ultrasound-guided injec‐
tions of PrP were effective in reducing pain in elbow tendinosis, medial epicondylitis [155]
and jumper's knee [156]. Until now, few high-quality studies on the use of autologous GF
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injections for the management of chronic tendinopathy showed no significant improvement
compared to a control group, but in those studies, autologous blood was injected and not
PrP [157-159]. Currently, there is level 3 (limited) evidence that PrP injections improve pain
or function in chronic tendinopathy [160]. More research on basic science and the clinical ap‐
plication of PrP needs to be undertaken before a final recommendation for PrP administra‐
tion for the treatment of tendinosis can be made [47, 160].
A study performed at our department showed that the administration of PrP when recon‐
structing ACL with a hamstring autograft enhances early graft revascularization in the inter‐
face zone between graft and bone in the tibial tunnel; furthermore, PrP stimulates the
formation of a sclerotic bony ring around the graft [161]. Platelet-leukocyte gel, applied lo‐
cally, can also improve knee stability in the first three-month period and especially in the
second three-month period [162]. Studies indicate that the delivery of PrP mimics and accel‐
erates physiological healing and reparative tissue processes in graft healing and graft liga‐
mentization process. Therefore, such therapy could improve knee stability and shorten the
period of rehabilitation after reconstructive knee surgery. However, not all studies on hu‐
mans confirm the positive effect of PrP. In one study after ACL reconstruction using patellar
tendon graft with the application of PrP, researchers did not find any statistically important
difference in inflammatory parameters, appearance of the graft on MRI, or clinical evalua‐
tion using validated scores [163]. Still others did not find any differences in graft fixation af‐
ter ACL reconstruction with hamstring allograft and application of PrP [164].
4.3. Extracorporeal shock wave therapy
Extracorporeal  shock wave therapy (ESWT) is  a technique used in the treatment of  ten‐
don disorders,  particularly  calcific  tendinopathy.  The  treatment  is  an  extension  of  renal
lithotripsy.  It  is  a  non-invasive  modality  used to  stimulate  healing,  particularly  in  liga‐
ment,  tendon, or bone structures.  A high-energy sound wave rapidly increases pressure
as it travels through the tissue, which results in cavitation that causes microtrauma. This
stimulates an increase in blood flow and new blood vessel  formation in the target area.
Studies showed an increase in inflammatory cytokines and growth factors, as well as the
regulation of tumour necrosis factor, interleukin, and bone morphogenetic protein follow‐
ing ESWT. Studies indicate that differentiated tenocytes are metabolically ‘‘activated’’ by
ESWT and significantly induced proliferation and production of collagen (mainly type I)
compared with untreated cells [165, 166]. Not all studies were able to show a positive ef‐
fect  of  ESWT,  but  this  was  later  argued to  be  a  possible  consequence  of  topical  anaes‐
thetics that interfere with ESWT treatment [167].
Numerous other substances have been used in the treatment of tendon disorders, including
sclerosants, calcium gluconate, heparin, dextrose, and aprotinin; however, more studies
have to be performed to prove their efficiency [168]. To date, no optimal treatment modali‐
ties for injured tendons or ligaments have been proposed. In fact, sheathed tendons may
heal differently from those not enclosed in sheaths and the process of healing of an intra-
articular ligament may differ from an extra-articular ligament. Recent studies support the
idea that scaffolds can provide an alternative for tendon augmentation and that tissue engi‐
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neering has an enormous therapeutic potential. In recent years studies revealed that tendon
healing and regeneration may be improved by the application of several growth factors and
the use of PrP expanded widely. Today, many different producers provide PrP of different
composition that makes studies hard to compare. Future studies will have to explain which
concentrations of PrP works the best, where it is effective and what the role of accompany‐
ing leucocytes is.
5. Conclusion
Regenerative medicine holds great promise for sports medicine with aim to develop novel
therapies that will replace, repair, or promote tissue regeneration. It is an increasingly ex‐
panding area of research with hopes of providing therapeutic treatments for diseases and/or
injuries that conventional medicines cannot effectively treat. Skeletal muscle has a great self-
regenerative capacity, but it is unfortunately limited by fibrotic infiltration. Although none
of the antifibrotic agents to improve skeletal muscle regeneration have been tested on hu‐
mans to date, its clinical implications are potentially far-reaching and include not only
sports-related injuries, but also diseases such as muscular dystrophies and trauma- and sur‐
gery-related injury. With emerging novel therapeutic targets this is an important area of re‐
search and presents a basis for further possibilities to study different mechanisms of action
and effects drug combinations for improving muscle regeneration.
Biomaterials play an important role in directing tissue growth and may provide another tool to
manipulate and control stem cell behaviour. Growth factors and therapies using mesenchymal
stem cells, scaffolds, and tissue engineering using bioreactors represent promising strategies
for tendon, ligament and cartilage repair. While therapies using growth factors seem to be well
established in case of the first two, lack of scientific evidence still makes them questionable. In
the future of cartilage repair, the modification of cellular differentiation following microfrac‐
ture could be alternated with the use of exogenous growth factors and scaffolds in order to re‐
tain chongrogenic phenotype and to improve the quality of repair tissue generated in the
defect. The important future prospective of cartilage repair is also focused on the quality of the
bonding and integration of the newly engineered tissue to native cartilage to achieve stable
healing. This holds potential for tissue-engineered strategies that would enable repairing com‐
plex cartilage lesions together with the subchondral bone and other structures. However, as
with all innovations, carefully conducted studies should be carried out to access the efficiency
for cartilage regeneration. Furthermore, long term prospective randomized studies are needed
to confirm the encouraging preliminary results.
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